Where does Novartis Vaccines and Diagnostics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Novartis Vaccines and Diagnostics, Inc. ranks #18,961 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Novartis Vaccines and Diagnostics, Inc. hold?

Novartis Vaccines and Diagnostics, Inc. holds 15 US utility patents granted between 2015 and 2021, spanning 8 technology areas.

What is Novartis Vaccines and Diagnostics, Inc.'s Innovation Score?

Novartis Vaccines and Diagnostics, Inc. has an Innovation Score of 31.5 out of 100 (38th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Novartis Vaccines and Diagnostics, Inc. focus on?

Novartis Vaccines and Diagnostics, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 14 patents, ranking #1,384 of 6,058 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Novartis Vaccines and Diagnostics, Inc.'s patent grant rate increasing or decreasing?

Novartis Vaccines and Diagnostics, Inc.'s recent grant velocity is -93% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Novartis Vaccines and Diagnostics, Inc.'s patents?

Novartis Vaccines and Diagnostics, Inc.'s patents average 19.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Novartis Vaccines and Diagnostics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Novartis Vaccines and Diagnostics, Inc.

USPTO PatentsView assignee record - 15 granted patents across 8 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Novartis ranks #18,961 of 49,997 tracked US assignees by granted-patent volume, with 15 patents across 8 technology areas.

#18,961
of 49,997 US assignees by volume: 38th percentile
by Innovation Score (31.5/100): 19.9
avg claims per patent: -93%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R18961 · US Corporation #18,961 · 15 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 15 grants
MID-PACK #18,961/49,997
PHOTO-FINISH Ningbo Litesun…
CPC-NARROW A61P · 8 areas
INNOV-THIN 31.5/100
CLAIMS-RICH 19.9 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -93% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Ningbo Litesun Electric Co., Ltd (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Novartis’s 31.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.6 pts (30%) Velocity 0.0 pts (0%) Breadth 10.0 pts (32%) Claim depth 11.9 pts (38%)

Qualcomm Incorporated · highest

85
Novartis Vaccines… · this assignee

32
3D Lighting… · lowest

7

What this shows Novartis's Innovation Score is 31.5/100 (38th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Novartis?

Each dot is one of Novartis’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Novartis’s own 19.9 claims/patent is ABOVE the 12.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Novartis vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Novartis's grants concentrate

Novartis Vaccines and Diagnostics, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 93.3% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (8 grants) versus a trough of 1 in 2018. By volume, Novartis sits between Ningbo Litesun Electric Co., Ltd and OCZ Storage Solutions Inc..

Ningbo Litesun El…

15
Ningbo Pureza Tec…

15
Nitta Haas

15
Nortek Air Soluti…

15
Novatel Wireless

15
Nozomi Networks S…

15
Obigo

15
OCZ Storage Solut…

15
Novartis Vaccines… ◀

15

What this shows Novartis holds 15 patents at rank #18,958, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Novartis

By rank, the assignees closest to #18,958 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Novartis's primary technology class.

Novartis's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 38th percentile higher than 38% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Novartis Vaccines and Diagnostics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	8	53.3%
2016	3	20.0%
2017	2	13.3%
2018	1	6.7%
2021	1	6.7%

Which technologies does Novartis Vaccines and Diagnostics, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 14

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 14

C07K - Peptides 11

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 6

Y02A - Technologies FOR Adaptation TO Climate Change 1

Y10S - Technical Subjects Covered BY Former Uspc Cross-reference ART Collections [XRACs] AND Digests 1

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 1

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Novartis Vaccines and Diagnostics, Inc.'s patent record in context - here's where to go next.

Novartis Vaccines and Diagnostics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 93.3% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #18,961 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Novartis Vaccines and Diagnostics, Inc. against Ningbo Litesun Electric Co., Ltd, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 31.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.